Posted by Michael Wonder on 22 Sep 2022
CADTH recommendation to not reimburse new treatment a failure for people living with schizophrenia
21 September 2022 - The Schizophrenia Society of Canada is joined by the schizophrenia community across Canada in its disappointment with the final recommendation by CADTH, the agency responsible for provincial reimbursement recommendations, that Vraylar (cariprazine) should not be publicly reimbursed for the treatment of schizophrenia in adults.
Vraylar is the only approved treatment for adults with schizophrenia that has also been shown to improve predominant negative symptoms and functioning – which clinical experts consulted by CADTH confirmed as an area of unmet need.
